-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48

Benzinga·03/19/2026 19:40:55
Listen to the news
Jefferies analyst Anthea Li assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and lowers Price Target of $48.